Advanced Biomedical Technologies : Quarterly Report for the period ended January 31, 2022

Disclosure Statement Pursuant to the Pink Basic Disclosure

Guidelines

Advanced Biomedical Technologies Inc.

200 Park Avenue, Suite 1700

New York City, NY 10166

_______________________________

[phone]

www.abtbiomedical.com

[e-mail]

3842

QuarterlyReport

For the Period Ending: January 31, 2022

(the "Reporting Period")

As of January 31, 2022, the number of shares outstanding of our Common Stock was:

70,604,850

As of October 31, 2021, the number of shares outstanding of our Common Stock was:

70,604,850

As of October 31, 2021, the number of shares outstanding of our Common Stock was:

70,604,850

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting period:

Yes: ☐

No: ☒

1. Name and address(es) of the issuer and its predecessors (if any)

Advanced Biomedical Technologies, INC. (fka "Geostar Mineral Corporation") ("ABMT", the "Company", "we", "our," or "us") was incorporated in Nevada on September 12, 2006.

1

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

200 Park Avenue, Suite 1700, New York City, NY 10166

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐

No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

1. Security Information

Trading symbol:	ABMT
Exact title and class of securities outstanding:	Common Stock
CUSIP:		37364M103
Par or stated value:	0.00001
Total shares authorized:	100,000,000as of date: January 31, 2022
Total shares outstanding:	70,604,850	as of date: January 31, 2022
Number of shares in the Public Float2:	9,375,209	as of date: January 31, 2022
Total number of shareholders of record:	57	as of date: January 31, 2022
Transfer Agent
Name:	Securities Transfer Corporation
Phone:	[phone]
Email:	www.stctransfer.com
Address: 2901 N. Dallas Parkway, Suite 380, Plano, TX 75093
Is the Transfer Agent registered under the Exchange Act?3 Yes: ☒	No: ☐

1. Issuance History

2

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent

Fiscal Year End:

Opening Balance

Date October 31, 2019
Common: 69,874,850
Preferred: 0
Date of	Transaction	Number of	Class of	Value of	Were the	Individual/ Entity	Reason for share	Restricted or	Exemption
Transaction	type (e.g. new	Shares	Securities	shares	shares	Shares were	issuance (e.g. for	Unrestricted	or
	issuance,	Issued (or		issued	issued at	issued to	cash or debt	as of this	Registration
	cancellation,	cancelled)		($/per	a discount	(entities must	conversion)	filing.	Type.
	shares			share) at	to market	have individual	-OR-
	returned to			Issuance	price at	with voting /	Nature of
	treasury)				the time	investment	Services
					of	control	Provided
					issuance?	disclosed).
					(Yes/No)
03/01/2020	New	100,000	Common	0.042	No	Puyi Sheng	Advisory	Restricted	NA
	Issuance		Stock				Service
10/27/2020	New	100,000	Common	0.153	No	Chiming Yu	Directors'	Restricted	NA
	Issuance		Stock				Service
10/27/2020	New	150,000	Common	0.153	No	Kai Gui	Directors'	Restricted	NA
	Issuance		Stock				Service
09/24/2021	New	80,000	Common	0.117	No	Puyi Sheng	Advisory	Restricted	NA
	Issuance		Stock				Service
10/26/2021	New	100,000	Common	0.0731	No	Chiming Yu	Directors'	Restricted	NA
	Issuance		Stock				Service
10/26/2021	New	200,000	Common	0.0731	No	Kai Gui	Directors'	Restricted	NA
	Issuance		Stock				Service
Shares Outstanding	on Date of This	Report:
Date 1/31/2022	Ending Balance
Common: 70,604,850
Preferred: 0

During the fiscal year ended October 31, 2020, the Company issued 350,000 new shares of its common stock as compensation for Advisory Service and Directors' Service. During the fiscal year ended October 31, 2021, the Company issued 380,000 new shares of its common stock as compensation for Advisory Service and Directors' Service.

B. Debt Securities, Including Promissory and Convertible Notes

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

3

Date of

Outstanding

Principal

Interest

Maturity

Conversion Terms (e.g.

Name of Noteholder

Reason for

Note

Balance ($)

Amount

Accrued

Date

pricing mechanism for

(entities must have

Issuance (e.g.

Issuance

at

($)

determining conversion of

individual with voting

Loan, Services,

Issuance

instrument to shares)

/ investment control

etc.)

($)

disclosed).

1. Financial Statements

A. The following financial statements were prepared in accordance with:

1. ☒ U.S. GAAP ☐ IFRS

2. The financial statements for this reporting period were prepared by (name of individual)4:

Name:	Kai Gui
Title:	Chief Financial Officer
Relationship to Issuer:	Principal Financial Officer

The following consolidated financial statements of the Company and its subsidiaries are included in this Quarterly Report at the pages noted below:

	Page
Condensed Consolidated Balance Sheets as of	12
January 31, 2022 and October 31, 2021 (unaudited)
Condensed Consolidated Statements of Operations and Comprehensive Income for the	13
three months ended January 31, 2022 and 2021 (unaudited)
Condensed Consolidated Statements of Changes in Shareholders' Equity for the	14
period from October 31, 2021 through January 31, 2022 (unaudited)
Condensed Consolidated Statements of Cash Flows for the	15
three months ended January 31, 2022 and 2021 (unaudited)
Notes to Condensed Consolidated Financial Statements	16
Management's Discussion and Analysis	19

4

1. Issuer's Business, Products and Services Organizational History

Advanced Biomedical Technologies, Inc. has one direct wholly owned subsidiary, Masterise Holdings Ltd., a limited liability company organized under the laws of British Virgin Islands ("Masterise"). Masterise, owns seventy percent (70%) of the issued and outstanding equity or voting interests in Shenzhen Changhua, a company formed under the laws of the People's Republic of China. (ABMT, Masterise, and Shenzhen Changhua are collectively referred to throughout this document as "We, "Us," "Our" (and similar pronouns), "ABMT" and the "Company").

We were incorporated in the State of Nevada on September 12, 2006. We maintain our statutory registered agent's office at The Corporation Trust Company of Nevada, 311 S Division Street, Carson City, Nevada 89703, and our business office is located at 200 Park Avenue, Suite 1700, New York City, NY 10166. We have not been subject to any bankruptcy, receivership, or similar proceeding, or any material reclassification or consolidation.

Our primary business is carried out by Masterise through Shenzhen Changhua, as set forth in the following diagram:

Shenzhen Changhua does not have any subsidiary.

Organizational History of Masterise and Shenzhen Changhua

Masterise is a wholly owned subsidiary of Advanced Biomedical Technologies, Inc.

Masterise is a limited liability company which was organized under the laws of British Virgin Islands ("BVI") on May 31, 2007, and owns 70% of the capital stock of Shenzhen Changhua.

Shenzhen Changhua is a limited liability company which was organized under the laws of PRC on September 25, 2002.

Since their founding, Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing, marketing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class

1. permit from the China Food and Drug Administration ("CFDA"), now the National Medical Products Administration of the PRC ("NMPA"). The Company holds three patents issued by the State Intellectual Property Office of the P.R.C. ("SIPO") and further patent applications are currently under review by the SIPO.

5